4//SEC Filing
Boissel Stephane 4
Accession 0001209191-19-045963
CIK 0001001233other
Filed
Aug 13, 8:00 PM ET
Accepted
Aug 14, 5:10 PM ET
Size
10.8 KB
Accession
0001209191-19-045963
Insider Transaction Report
Form 4
Boissel Stephane
EVP, Corporate Strategy
Transactions
- Exercise/Conversion
Free Shares Put Option (right to sell to Issuer)
2019-08-12−1→ 3 totalExercise: $2.37From: 2019-07-04Exp: 2021-02-03→ Common Stock (11,137 underlying) - Exercise/Conversion
Common Stock
2019-08-12+11,137→ 28,637 total - Disposition to Issuer
Common Stock
2019-08-12$11.23/sh−11,137$125,069→ 17,500 total
Footnotes (2)
- [F1]In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) ("Sangamo France"), the Reporting Person was granted the right to sell to the Issuer up to 238,100 "free shares" of Sangamo France (the "Subject Free Shares") for cash in four separate tranches beginning July 4, 2019 (the "Free Shares Put Options"). The exercise price per Subject Free Share to be paid by the Issuer upon the Reporting Person's exercise of its Free Shares Put Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Reporting Person notifies the Issuer of its exercise of its Free Shares Put Options (as converted to euros) divided by 12.8329. On August 12, 2019, the Reporting Person exercised his Free Shares Put Option with respect to the first tranche of Subject Free Shares (SEE FOOTNOTE (2) FOR CONTINUATION OF EXPLANATION)
- [F2](or 52,700 Subject Free Shares) (the "First Tranche Shares") in exchange for a cash payment of 111,724 euros, or approximately 2.12 euros per First Tranche Share. The Reporting Person's exercise of his Free Shares Put Option with respect to the First Tranche Shares for cash is deemed, for reporting purposes, to involve the conversion of the First Tranche Shares into shares of the Issuer's common stock and the simultaneous disposition of such common stock to the Issuer for cash. The August 12, 2019 euro to U.S. dollar exchange rate of 1.1194 was used for purposes of reporting the exercise price and the number of shares of the Issuer's common stock that was deemed to have been acquired and simultaneously disposed of by the Reporting Person upon exercise.
Documents
Issuer
SANGAMO THERAPEUTICS, INC
CIK 0001001233
Entity typeother
Related Parties
1- filerCIK 0001755198
Filing Metadata
- Form type
- 4
- Filed
- Aug 13, 8:00 PM ET
- Accepted
- Aug 14, 5:10 PM ET
- Size
- 10.8 KB